Jay Chanmugam, DO
Emergency Medicine · Orange City, FLNPI 1518905207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 29.9% of the total. 2025 is the largest year on record at $2,656, 5.6 times the $478 reported in 2019. Among emergency medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $29.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$839
- GSK$523
- Indivior Inc.$388
- Lilly USA, LLC$384
- plus $3K from 27 others
Across 6 payments — averaging $7044.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$40K
- Melinta Therapeutics, LLC$3K
What the payments were for
- Food & beverage$9,121100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $2,724 |
| AstraZeneca | 33 | $1,627 |
| Novo Nordisk | 36 | $839 |
| GSK | 22 | $523 |
| Indivior Inc. | 25 | $388 |
| Lilly USA, LLC | 8 | $384 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $354 |
| Amgen | 7 | $295 |
| Eisai Inc. | 4 | $275 |
| Braeburn Inc. | 12 | $249 |
| Exact Sciences | 9 | $173 |
| Johnson & Johnson | 3 | $163 |
| Pfizer | 8 | $145 |
| Teva Pharmaceuticals USA, Inc. | 2 | $140 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $100 |
| Orexo US, Inc. | 6 | $91 |
| Boston Scientific | 1 | $86 |
| Scilex Pharmaceuticals Inc. | 5 | $85 |
| Insulet Corporation | 4 | $69 |
| Abbott | 2 | $36 |
| Aytu Biopharma, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $28 |
| Bayer | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Merck | 1 | $23 |
| Axonics, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Photonicare Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,121 in reported general payments places this provider in the 95th percentile of 3,289 emergency medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 50 | $166,262 |
| UbrelvyUbrogepant | 35 | $104,848 |
| OzempicSemaglutide | 47 | $92,299 |
| FarxigaDapagliflozin Propanediol | 66 | $88,439 |
| MounjaroTirzepatide | 43 | $82,873 |
| EliquisApixaban | 77 | $71,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $69,431 |
| VraylarCariprazine Hcl | 46 | $64,659 |
| RybelsusSemaglutide | 28 | $50,444 |
| QuliptaAtogepant | 16 | $43,163 |
| XareltoRivaroxaban | 40 | $42,905 |
| Lidocaine | 60 | $28,177 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $25,673 |
| IsentressRaltegravir Potassium | 11 | $21,479 |
| MyrbetriqMirabegron | 14 | $15,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Vraylar, Qulipta, Linzess | $2,724 | $227,534112 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $839 | $144,96886 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,627 | $120,869119 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $145 | $89,183102 claims |
| Lilly USA, LLCMounjaro | $384 | $82,87343 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $523 | $73,27088 claims |
| Johnson & JohnsonXarelto | $163 | $42,90540 claims |
| MerckIsentress | $23 | $21,47911 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $15,70514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,289 emergency medicine providers in Florida.
Other emergency medicine in Orange City
- Laurent DreyfussSunrise$1.2M
- Jason WilsonTampa$538K
- Robert LutenJacksonville$190K
- Adam LeisyHialeah$148K
- Joseph TyndallGainesville$130K
- Kunal AgarwalMiami$101K
- Jason WilsonFort Myers$96K
- Latha GantiGainesville$86K
- Brandon AllenGainesville$80K
- Patricia PanakosMiami$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.